RxDoctor Payments Data

Raymond Thomas, MD

Gastroenterology · Canandaigua, NYNPI 1811034275

Payments from drug & device makers

$664in general payments, 2019–2025

Across 28 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$173
  • Pfizer$130
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$99
  • ERBE USA Inc$55
  • Takeda Pharmaceuticals U.S.A., Inc.$50
  • Regeneron Healthcare Solutions, Inc.$44
  • plus $112 from 6 others

What the payments were for

  • Food & beverage$664100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$664 in reported general payments places this provider in the 30th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$74,001
Medicare patients
352
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide77$53,321
Mesalamine65$25,043
Colesevelam Hcl252$20,923
Pantoprazole Sodium1,222$12,905
Sucralfate56$9,487
SutabSod Sulf/Pot Chloride/Mag Sulf50$8,003
Esomeprazole Magnesium156$6,423
Budesonide DrBudesonide39$4,449
Dexlansoprazole DrDexlansoprazole18$4,444
Colestipol Hcl42$4,400
Famotidine322$4,377
Ursodiol21$4,162
Budesonide EcBudesonide36$3,618
Omeprazole159$2,118
Lansoprazole52$1,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$173$53,32177 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Canandaigua

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →